October 17, 2019
  • October 17, 2019
Breaking News

Tag Archives

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study

by on July 2, 2019 0
Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. The data from the trial are supportive of the primary study... Read More

Pfizer Inc. (NYSE:PFE) named former FDA Commissioner Scott Gottlieb to its board of directors

by on June 28, 2019 0
Pfizer Inc (NYSE:PFE) said it has named former U.S. Food and Drug Administration Commissioner Scott Gottlieb to its board of directors, effective immediately. Gottlieb stepped down abruptly as the FDA chief in March this year, a role he had held since May 2017. Pfizer Inc. (NYSE:PFE), a Healthcare sector firm, traded 20.79 Million shares in last... Read More

FDA approved Pfizer Inc. (NYSE:PFE) oncology biosimilar Zirabev

by on June 28, 2019 0
Pfizer Inc. (NYSE:PFE) said the U.S. Food and Drug Administration has approved its oncology biosimilar Zirabev for the treatment of five types of cancer. The FDA has approved the drug to treat metastatic colorectal cancer, unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent,... Read More

FDA granted Orphan Drug Designation for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) lead product

by on June 28, 2019 0
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) said the FDA has granted Orphan Drug Designation for its lead product candidate ARCT-810 to treat ornithine transcarbamylase deficiency – the most common urea cycle disorder that makes it difficult for the removal of toxic waster products as proteins are digested. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a Financial sector... Read More

Healthcare Mover: Acasti Pharma Inc. (NASDAQ:ACST), Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb Company (NYSE:BMY)

by on June 27, 2019 0
Acasti Pharma Inc. (NASDAQ:ACST) loss for fiscal 2019 expanded from $21.5 million in the prior year to $51.6 million due to higher R&D costs for the TRILOGY Phase 3 program and other financial expenses. The company ended the year with $34.4 million in cash $26.2 million more than than the prior year on the basis of net proceeds from... Read More

After-Hours Bulls: Ford Motor Company (NYSE:F), Pfizer Inc. (NYSE:PFE), General Electric Company (NYSE:GE), Keurig Dr Pepper Inc. (NYSE:KDP)

by on June 25, 2019 0
Ford Motor Company (NYSE:F) has finished a $1 billion renovation at its two plants on Chicago’s far South Side. The company’s oldest continuously producing plant was transformed into a high-tech facility entrusted with building the new Ford Explorer. “When you build 350,000 vehicles a year through a facility year after year and you’re running... Read More

Pfizer Inc. (NYSE:PFE) received approval from the European Commission for breast cancer drug TALZENNA

by on June 24, 2019 0
Pfizer Inc. (NYSE:PFE) has received approval from the European Commission for its TALZENNA a breast cancer drug. This approval follows the medicine’s approval by the U.S. Food and Drug Administration in October 2018. “Today’s approval of TALZENNA for certain patients with advanced-stage breast cancer and an inherited BRCA mutation is the latest example of our... Read More